📃 Paper Title: Five year results of the prospective randomized controlled prostate urethral L.I.F.T. study
🧍 Author: Claus Roehrborn
🕒 Year: 2017
📚 Journal: Canadian Journal of Urology
🌎 Country: USA
ㅤContext to the study:
What advantages does UroLift have for the treatment of benign prostatic obstruction?
ㅤ✅ Take-home message of study:
In this 5-year follow-up of an international multicentre blinded sham-controlled randomised-controlled trial, UroLift under local anaesthetic for 30-80mL prostates demonstrates durable improvements in LUTS, flow and quality-of-life without compromise in sexual function, causing incontinence, or other safety concerns.
ㅤ Multicentre sham-controlled blinded randomised-controlled trial
ㅤ
Study participants:
206 patients across 19 centres (USA, Canada, Australia) who were >=50 years old with IPSS >12, Qmax <=12 mL/s, and with prostate volume 30-80mL were randomised 2:1 to UroLift (140) or blinded sham control (66). Those with an obstructive median lobe and active UTI were excluded. This paper details the 5 year follow-up data.
ㅤ
ㅤ
Key study outcomes:
96 patients had 5 year data available (i.e. follow-up between 49 and 60 months). Improvement in IPSS was 88% greater than sham at 3 months. LUTS and quality of life were significantly improved by 2 weeks, with a return to pre-operative physical activity within 8.6 days. IPSS, quality of life, BPHII and Qmax measures showed durable improvements through 5 years (36%, 50%, 52%, and 54%, respectively). 13.6% needed surgical retreatment over 5 years. No patient had any new, sustained erectile or ejaculatory dysfunction.
ㅤ
ㅤ
Study Limitations:
As with any long-term follow-up, there is attrition of patients and therefore follow-up measures can become less accurate
For the North American centres, the UroLifts performed here were their first such procedures and therefore surgeons were inexperienced compared to the modern day where more surgeons have UroLift experience
It is unclear how UroLift may perform in larger prostates
ㅤ